FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPRO	VAL
OMB Number:	3235-0287
Estimated average b	ourden
nours per response.	0.5

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * MARIO ERNEST			*	2. Issuer Name and Ticker or Trading Symbol Tonix Pharmaceuticals Holding Corp. [TNXP]					ון	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
(Last) (First) (Middle) C/O TONIX PHARMACEUTICALS HOLDING CORP., 509 MADISON AVENUE, SUITE 306 (Street) NEW YORK, NY 10022			SHOLDING	3. Date of Earliest Transaction (Month/Day/Year) 02/09/2016 4. If Amendment, Date Original Filed(Month/Day/Year)						A Director				w)	
														ine)	
(City) (State) (Zip)			(Zip)		1	Гable I	- Non	-Derivati	ve Securitie	es Acquirec	lired, Disposed of, or Beneficially Owned				
1.Title of Se (Instr. 3)	ecurity	D	Transaction late Month/Day/Year)	2A. Deemed Execution I any (Month/Day	Date, i	f Code (Inst		(A)	ecurities Ac or Disposed tr. 3, 4 and 5 (A) or ount (D)	of (D) Ber S) Rej (In	neficially (nsaction(s)	F C O	orm: Evirect (D) Cr Indirect (Beneficial Ownership
Reminder: R							c	containe		rm are no	ot require		ond unless		474 (9 - 02)
remilder. N			Table II - I	Derivative S	lecuri	ties Ac	f	containe form disp	d in this fo plays a cui	orm are no	ot require	d to resp	ond unless		474 (9-02)
1. Title of Derivative Security	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year	3A. Deemed Execution Date	Code	alls, w	varrant 5. Num 6. Num 6. Derivat 8. Securiti 9. Acquire (A) or 10. Dispose 10. Of (D)	equirects, option of the control of	containe form disp d, Dispose	d in this foolays a cuited of, or Berertible securcisable ion Date	orm are no rrently val	ot require lid OMB of Owned d f	ed to respondent of the second	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s	10. Ownershi Form of Derivativ Security: Direct (D or Indirect)	11. Natrop of Indire Benefic Owners (Instr. 4
1. Title of Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date any	4. t, if Transac Code	stion of I	Arranto 5. Number 5. Number 6. Derivate 6. Securition 6. Acquire 6. A) or 6. Dispose	equirects, option of the control of	contained form disp d, Disposed ions, conv Date Exe nd Expirat	d in this foolays a cuited of, or Berertible securcisable ion Date	rently value of the control of the c	ot require lid OMB of Owned d f	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported	10. Ownershi Form of Derivativ Security: Direct (D or Indirec	11. Nati p of Indir Benefic Owners (Instr. 4
1. Title of Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date any	4. t, if Transac Code	stion of I	5. Num 5. Num 6. Derivat 6. Securiti 6. Acquire 6. A) or 7. Dispose 6. Dispos	equirects, optimized ber arrive (Nies ed arrive arrive arrive) arrive ed arrive (Nies ed arrive arri	contained form disp d, Disposed ions, conv Date Exe nd Expirat	d in this foolays a cui	rently value of the control of the c	ot require lid OMB of Owned d f	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s	10. Ownershi Form of Derivativ Security: Direct (D or Indirect)	11. Nat p of Indir Benefic Owners (Instr. 4

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
MARIO ERNEST C/O TONIX PHARMACEUTICALS HOLDING CORP. 509 MADISON AVENUE, SUITE 306 NEW YORK, NY 10022	X					

Signatures

/s/Jessica Morris, Attorney-in-Fact	02/10/2016
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Each restricted stock unit represents the right to receive, at settlement, one share of common stock.
- (2) These restricted stock units are scheduled to vest 100% on February 9, 2017.
- (3) The restricted stock units were granted pursuant to the Issuer's 2014 Stock Incentive Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.